Posted On: 09/08/2014 1:12:13 AM
Post# of 30037
The Company has been advised by various stakeholders in the larger capital markets community that it is best for the Company to achieve an appropriate capital structure while still on the OTC Markets so that the cap structure risk is mitigated once on a national exchange. In addition to an increase in the number of our authorized shares, we are seeking shareholder approval for various other matters that will better position the Company for the up-list to a national exchange.
Many of you are likely asking how the Company can possibly expect to up-list to a national exchange in 2014 without the need for a reverse split of its common shares. The answer is that the Company does not know where its common shares will be priced towards the end of this year, and therefore cannot project what will be required in terms of a reverse split or if a reverse split will be needed. However, we remain optimistic that we can significantly increase shareholder value through value building events both from a scientific and clinical perspective, as well as a capital markets perspective:
In the last 2 years, we have created, year over year, between 200%-300% returns for our shareholders and we believe that in order to continue that trend we must take the important step of moving from the OTC to a national listing. In doing so, larger institutional investors can participate in a meaningful way in the value creation here at Amarantus, and give the Company better negotiating leverage with end-buyers in the biopharmaceutical arena who use lack of resources as the primary leverage point with any smaller potential partner with compelling science. - See more at: http://www.thechairmansblog.com/amarantus-bio...eDI8m.dpuf
Many of you are likely asking how the Company can possibly expect to up-list to a national exchange in 2014 without the need for a reverse split of its common shares. The answer is that the Company does not know where its common shares will be priced towards the end of this year, and therefore cannot project what will be required in terms of a reverse split or if a reverse split will be needed. However, we remain optimistic that we can significantly increase shareholder value through value building events both from a scientific and clinical perspective, as well as a capital markets perspective:
In the last 2 years, we have created, year over year, between 200%-300% returns for our shareholders and we believe that in order to continue that trend we must take the important step of moving from the OTC to a national listing. In doing so, larger institutional investors can participate in a meaningful way in the value creation here at Amarantus, and give the Company better negotiating leverage with end-buyers in the biopharmaceutical arena who use lack of resources as the primary leverage point with any smaller potential partner with compelling science. - See more at: http://www.thechairmansblog.com/amarantus-bio...eDI8m.dpuf
(0)
(0)Scroll down for more posts ▼
